MSKCC in the News: March 8 – March 21

Posted on March 20, 2012 by Mark

The members of the American Association for Cancer Research have elected MSKCC’s Charles L. Sawyers, M.D., as their president-elect for 2012-2013.
The New England Journal of Medicine published an MSKCC study that found that high-dose chemotherapy improved the rate of survival for patients with three specific genetic mutations, compared with standard-dose chemo.
Researchers from MSKCC and St. Jude Children’s Research Hospital have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults.

MSKCC in the News: February 23 – March 7

Posted on March 5, 2012 by Mark

For the first time, a new MSKCC study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease.
IBM announced that Dr. Spriggs of MSKCC will join its Watson Healthcare Advisory Board. The advisory board will specifically focus on medical industry trends, clinical imperatives, regulatory considerations, privacy concerns and patient and clinician expectations around Watson technology and how it can be incorporated into clinician workflows.

Posted on February 20, 2012 by Mark

MSKCC’s Dr. Howard I. Scher presented results of a study that showed that targeted therapy improves overall in men with advanced PCa.
MSKCC will be among 4 different research centers tasked with the mission of solving problems related to mesothelioma and treatment for it.
Dr. Christopher Park of MSKCC is the lead researcher of a study that supports the theory that myelodysplastic syndromes has its origins in bone marrow stem cells.